Pay in 4 interest-free payments of $22.31 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Therefore KDM5-C70 was developed as a pro-drug
heme oxygenase-1 (HO1
636:276-281
PubMed PMID: 29523028
mouthwash and chewing gum -in which it has an antimicrobial effect on the microbes responsible for bad breath- or skin care products)
Nilotinib (monohydrochloride monohydrate) - CAS# 923288-90-8 rasirox (Fe3+ chelate) Therefore KDM5-C70 was developed asNilotinib, also known as AMN107, is a small molecule tyrosine kinase inhibitor approved for the treatment of imatinib resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr Abl kinase inhibitor that is 10 30 fold more potent than imatinib in inhibiting Bcr Abl tyrosine kinase activity and
US$ 172.50
US$ 128.50
US$ 116.50
US$ 154.00
US$ 157.50